english.prescrire.org > Spotlight > 100 most recent > Dexrazoxane in children: European disagreements and arbitration

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the October issue of Prescrire International - Dexrazoxane in children: European disagreements and arbitration

FREE DOWNLOAD In 2017, dexrazoxane was re-approved in the European Union for use in children treated with high doses of anthracyclines. However, uncertainties remain.
Full text available for free download.

Summary

  • Since its introduction onto the European market in the 1990s, evaluation of dexrazoxane is insufficient to determine its harm-benefit balance.
     
  • Nearly 20 years on, disagreement between agencies shows that substantial uncertainties remain.

Full text available for free download.

 ©Prescrire 1 October 2018

"Dexrazoxane in children: European disagreements and arbitration" Prescrire Int 2018; 27 (197): 245. (Pdf, free)

Share Share on Facebook Share on Twitter
Share
Partager sur Facebook Partager sur Twitter

 
Download the full review
Pdf, free